Compare Inovio Pharmaceuticals Inc (INO) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Clear Secure Inc is far larger — about 39.6× Inovio Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Clear Secure Inc for 19 Days on average.
| INO | YOU | |
|---|---|---|
Market Cap | $112.19M | $4.44B |
Volume | 3,201,278 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $2.65 | $62.36 |
52-Week Low | $0.66 | $29.61 |
Typical Hold Time | 43 Days | 19 Days |
Enterprise Value | $83.51M | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Clear Secure (YOU) trades at $43.08, up 1.17% with strong fundamentals including 27% revenue growth and expanding profitability. The stock shows mixed technical signals with bullish overall momentum but overbought RSI levels. Recent Q2 earnings beat expectations with $0.49 EPS versus $0.40 estimate, while analyst consensus targets $61.40 representing 43% upside potential.
Outlook remains positive with accelerating membership growth and new corporate partnerships driving expansion. Key risks include competitive pressure in identity verification and potential execution challenges. The stock offers growth exposure but requires monitoring of technical overbought conditions and quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
